Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP

Tonix Pharmaceuticals — Investor Presentation (July 2024)

14 slides from Tonix Pharmaceuticals's investor presentation, Jul 15, 2024

  1. Slide 1: Broad-spectrum Host-directed Therapeutics: CD45 Inhibitor as Antiviral

    Broad-spectrum Host- directed Therapeutics: CD45 Inhibitor as Antiviral July 2024 NASDAQ: TNXP Version P0576 July 15, 2024 (Doc 1476) © 2024 Tonix Pharmaceuticals Holding Corp.

  2. Slide 2: Cautionary Note on Forward-Looking Statements

    Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be i

  3. Slide 3: Tonix Awarded $34M Contract from DTRA/DoD

    Tonix Awarded $34M Contract from DTRA/DoD INFECTIOUS DISEASE PORTFOLIO DTRA contract is expected to advance development of Tonix’s broad-spectrum oral antiviral program (TNX-4200) for medical countermeasures • Other Transaction Agreement (OTA) with a potential for up to $34 million over five years O

  4. Slide 4: DoD Moves Beyond "One Drug, One Bug" Approach

    DoD Moves Beyond “One Drug, One Bug” Approach1,2 INFECTIOUS DISEASE PORTFOLIO • The US Department of Defense (DoD) is moving beyond the traditional “one drug, one bug” approach to antivirals, and embracing the “one drug, multiple bugs” approach to protect against viral illness in warfighters • The D

  5. Slide 5: Broad-spectrum Host Directed Antiviral Drug Development vs Virus-specific Approaches

    Broad-spectrum Host Directed Antiviral Drug Development vs Virus-specific Approaches INFECTIOUS DISEASE PORTFOLIO Conventional Approach Broad Spectrum Antivirals1 Single Virus Family Broad Spectrum Virus-Targeted2 Virus-Targeted Host-Targeted Drug Virus Drug Virus Drug Virus Biktarvy® HIV Veklury® C

  6. Slide 6: Enhancing Viral Immunity Has the Potential to Protect Against Viral Diseases

    Enhancing Viral Immunity Has the Potential to Protect Against Viral Diseases INFECTIOUS DISEASE PORTFOLIO Too Little Spectrum of Immunity Too Much Immune Suppression Autoimmunity Therapeutic Zone Tone down the Rev up the immune system immune system to treat: to treat: Autoimmunity examples: Cancer e

  7. Slide 7: Enhancing Viral Immunity by Inhibiting CD45 Phosphatase

    Enhancing Viral Immunity by Inhibiting CD45 Phosphatase INFECTIOUS DISEASE PORTFOLIO • CD45 is a transmembrane protein tyrosine phosphatase (PTPase) expressed on most hematopoietic cells, including T lymphocytes • CD45 regulates receptor signaling pathways, particularly T cell activation • It dephos

  8. Slide 8: Kinases Enhance and Phosphatases Modulate Immune Responses

    Kinases Enhance and Phosphatases Modulate Immune Responses INFECTIOUS DISEASE PORTFOLIO Kinases enhance CD45 phosphatase immune responses modulates immune responses CD45 phosphatase Kinases add phosphate “P” to removes phosphate “P” signaling molecules From signaling molecules 8 Panchal RG, et al.,

  9. Slide 9: Phosphatase Inhibitors Decrease Enzymatic Activity of CD45 and Potentially Enhance Viral Immunity

    Phosphatase Inhibitors Decrease Enzymatic Activity of CD45 and Potentially Enhance Viral Immunity INFECTIOUS DISEASE PORTFOLIO CD45 phosphatase Kinases enhance immune responses 9 Panchal RG, et al. J Biol Chem. 2009 284(19):12874-85. doi: 10.1074/jbc.M809633200. © 2024 Tonix Pharmaceuticals Holding

  10. Slide 10: TNX-4200: Orally Available CD45 Antagonists

    TNX-4200: Orally Available CD45 Antagonists INFECTIOUS DISEASE PORTFOLIO • Tonix is exploiting regenerative AI and computational biology to identify modulators of CD45 expression and inhibitors of CD45 function to develop candidate broad- spectrum antiviral drugs1 Goal: broad spectrum antivirals CD4

  11. Slide 11: Tonix Research and Development Center (RDC)

    Tonix Research and Development Center (RDC) INFECTIOUS DISEASE PORTFOLIO • Located in Frederick, MD (close to Fort Detrick/ USAMRIID) • 48,000 square foot facility; main building is BSL-2 with some areas designated BSL-3 • Supports expanding infectious disease pipeline by accelerating internal disco

  12. Slide 12: Sina Bavari, PhD – Director of Infectious Disease Research

    Sina Bavari, PhD – Director of Infectious Disease Research INFECTIOUS DISEASE PORTFOLIO • Sina Bavari, PhD, Tonix’s Executive Director of Infectious Disease R&D ‒ Formerly served as head of science at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) • At DoD/USAMRI

  13. Slide 13: Other Programs at Tonix: Non-dilutive Funding

    Other Programs at Tonix: Non-dilutive Funding INFECTIOUS DISEASE PORTFOLIO • Tonix has other broad spectrum antiviral programs ongoing ‒ Cathepsin inhibitors ‒ Protein-engineered lectins • Other Government Support ‒ Tonix’s TNX-1800 vaccine was selected by the National Institutes of Health (NIH), th

  14. Slide 14: Thank You

    THANK YOU © 2024 Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding — Investor Presentation (July 2024) on 6ix